Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Adverse Drug Response Risk Gene Identified for IBD

By LabMedica International staff writers
Posted on 28 Mar 2019
Investigators have uncovered genetic variants in a gene called Nudix hydrolase 15 (NUDT15) that seem to coincide with treatment-related complications in individuals of European ancestry with inflammatory bowel disease (IBD).

Roughly 15% of IBD patients treated with thiopurines such as mercaptopurine experience adverse drug responses that require them to discontinue treatment. More...
For example, past studies suggest that genetic variants in a TPMT gene coding for a thiopurine S-methyltransferase enzyme are involved in producing methylated, less active metabolites from thiopurine drugs.

A large international team led by those at the Royal Devon and Exeter Hospital (Exeter, UK) carried out a case-control study of 491 patients affected by thiopurine-induced myelosuppression (TIM) and 679 thiopurine-tolerant unaffected patients who were recruited from 89 international sites between March 2012 and November 2015. Genome-wide association studies (GWAS) and exome-wide association studies (EWAS) were conducted in patients of European ancestry. The replication cohort comprised 73 patients affected by TIM and 840 thiopurine-tolerant unaffected patients. TIM was defined as a decline in absolute white blood cell count to 2.5 × 109/L or less or a decline in absolute neutrophil cell count to 1.0 × 109/L or less leading to a dose reduction or drug withdrawal. The team used Illumina Infinium arrays to genotype 311 IBD patients with and 608 without thiopurine-induced myelosuppression at nearly 245,200 variants.

The team reported that the GWAS analysis confirmed association of TPMT (chromosome 6, rs11969064) with TIM 95/311 (30.5%) affected versus 100/608 (16.4%) unaffected patients; odds ratio [OR], 2.3). The EWAS analysis demonstrated an association with an in-frame deletion in NUDT15 (chromosome 13, rs746071566) and TIM 19/328 (5.8%) affected versus 1/633 (0.2%) unaffected patients; OR, 38.2, which was replicated in a different cohort (2/73 (2.7%) affected versus 2/840 (0.2%) unaffected patients; OR, 11.8. Carriage of any of 3 coding NUDT15 variants was associated with an increased risk (OR, 27.3) of TIM, independent of TPMT genotype and thiopurine dose.

The authors concluded that among patients of European ancestry with IBD, variants in NUDT15 were associated with increased risk of TIM. These findings suggest that NUDT15 genotyping may be considered prior to initiation of thiopurine therapy; however, further study including additional validation in independent cohorts is required.

Gareth Walker, MRCP, a gastroenterology specialist and first author of the study, said, “We hope that once a predictive test is developed, patients will be able to have a simple blood test before starting these drugs. This will allow doctors to modify treatments, either by reducing the dose or opting for different treatment altogether.” The study was published on February 26, 2019, in the Journal of the American Medical Association.

Related Links:
Royal Devon and Exeter Hospital


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR Setup
ESTREAM
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.